digital currency cards

Ai Kelan: The actual controller intends to transfer 5% shares of the company by agreement. Ai Kelan announced that Liu Yi, the controlling shareholder and actual controller of the company, intends to transfer 4 million unrestricted shares of the company to Guangdong Nanchuan Private Equity Fund Management Co., Ltd. by agreement transfer, accounting for 5.00% of the company's total share capital. If the transaction is finally completed, Liu Yi holds 33.89% of the company's shares, and Nanchuan Private Equity holds 5.00% of the company's shares. This change in equity will not lead to changes in the controlling shareholder and actual controller of the company. The transfer of shares in this agreement can only be handled in Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. after the compliance confirmation of Shenzhen Stock Exchange. The share transfer price of this transaction is 20.61 yuan/share.Kremlin spokesman: (Asked if Putin has been invited to attend Trump's inauguration ceremony) No invitation has been received.Mengke Pharmaceutical Co., Ltd.: The new packaging of Contizontamide tablets will be on the market soon. Mengke Pharmaceutical Co., Ltd. announced that the company has launched Contizontamide tablets with new packaging specifications, and a box of 12 tablets will be on the market soon. Contizontamide tablet is a new class 1 oxazolidinone antibacterial drug with global intellectual property rights. It was approved by National Medical Products Administration, China on June 1st, 2021 for the treatment of complex skin and soft tissue infections.

In the latest centralized purchase of sitagliptin tablets, the price dropped to less than 20 cents per tablet, with a drop of over 90%. The reporter learned at the scene of the tenth batch of drug centralized purchase that more than 30 companies bid for sitagliptin, which is known as the largest variety in this centralized purchase, including Huahai Pharmaceutical, Kelun Pharmaceutical, Zhengda Tianqing, tonghua dongbao, Zhejiang Pharmaceutical, Jiudian Pharmaceutical, Shiyao Ouyi, Chenxin Pharmaceutical and many other companies. Judging from the bidding results, the lowest bid price among enterprises has dropped below 0.2 yuan per piece, which is more than 90% lower than the limit price. Statistics show that in 2023, the sales of this product in the terminals of public medical institutions in China exceeded 2 billion yuan, and the sales of Merck, the original research manufacturer, accounted for more than 90%, so there is a large room for generic drug substitution. The quotation of Meradong in this collection is about 7.37 yuan per piece. (science and technology innovation board Daily)Botuo Bio: Adjust the profit distribution plan for the first three quarters of 2024. Botuo Bio announced that the total amount of cash dividends to be distributed in the company's profit distribution for the first three quarters of 2024 was adjusted from RMB 52.2583 million to RMB 53.2083 million. Before the adjustment, the company's total share capital was 105 million shares after deducting the shares in the company's repurchase special securities account, and a total cash dividend of 52.2583 million yuan was planned to be distributed. After adjustment, the company's total share capital is 107 million shares, of which 250,000 shares are repurchased in the special securities account, and the total number of shares actually participating in the profit distribution of the company is 106 million shares, with a total cash dividend of 53,208,300 yuan.Schlegel, Governor of the Swiss National Bank: We will continue to monitor inflationary pressure and adjust monetary policy to maintain price stability if necessary. Without today's interest rate cut, inflation expectations would be lower. The uncertainty of the future inflation path is still high. The medium-term inflationary pressure has dropped significantly.

Liu Shijin: To expand consumption, we should manage from the source, and give priority to improving basic public services and consumption of low-and middle-income groups. Liu Shijin, deputy director of the 13th Chinese People's Political Consultative Conference Economic Commission and former deputy director of the the State Council Development Research Center, pointed out in his speech at the main forum of the 2024 Southern Finance and Economics International Forum that the macro-economy is picking up, but it is also facing the increasing pressure of insufficient total demand, especially insufficient consumer demand, and the focus of which is insufficient service consumption. We should give priority to improving basic public services and the consumption environment of low-and middle-income groups through "source governance" to promote the integrated development of urban and rural areas. On the basis of short-term stimulus policies, combined with medium-and long-term reforms, we will solve the institutional problems that restrict the expansion of consumption and help China's economy achieve high-quality development. "At present, it is necessary to distinguish the problems caused by insufficient demand from the causes of insufficient demand." Liu Shijin pointed out that from the perspective of international comparison, the lack of consumption demand in China at this stage is a structural deviation. In Liu Shijin's view, it is necessary to identify the key points or pain points in expanding consumer demand at this stage. First, service consumption based on basic public services, including education, medical and health care, affordable housing, social security, culture, sports and entertainment, financial services, transportation and communication; Second, the middle and low-income class with migrant workers as the focus; Third, people-centered, urbanization and urban-rural integration. (21 Finance)Xiamen Tungsten Xinneng: Signed a strategic cooperation framework agreement for solid-state batteries with Xinwangda Power. Xiamen Tungsten Xinneng announced that the company and Xinwangda Power signed the Strategic Cooperation Framework Agreement for Solid-state Batteries on December 11, 2024. The two sides will give full play to their respective advantages in market and technology, promote the industrialization of a series of new energy battery materials for solid-state batteries, establish a deep-seated strategic cooperative relationship, jointly develop a series of new energy battery materials for solid-state batteries, and further expand business cooperation at an appropriate time.Dagang shares: the bankruptcy proceedings of China University of Science and Technology Port have ended, and Dagang shares announced that the bankruptcy proceedings of Jiangsu University of Science and Technology Port Laser Technology Co., Ltd., a holding subsidiary of the company, have ended. Since the bankruptcy administrator took over the port of China University of Science and Technology, it is no longer included in the scope of the company's consolidated statements.